

Biotechnology


IMMP - NASDAQ

July 30, 2018

Intraday Price 07/30/2018	\$2.47
Rating:	Buy
12-Month Target Price:	\$7.00
52-Week Range:	\$1.25 - \$3.06
Market Cap (M):	75
Shares O/S (M):	30.3
Float:	100.0%
Avg. Daily Volume (000):	87
Debt (M):	\$6.2
Dividend:	\$0.00
Dividend Yield:	0.00%
Risk Profile:	Speculative
Fiscal Year End:	June

Total Expenses ('000)

	2017A	2018E	2019E
H1	3,716	7,440A	6,864
H2	6,917	6,877	7,436
FY	10,633	14,317	14,300



Immutep Limited

Buy

Reports June Quarter: Cash Runway Through Several Data Points in the LAG-3 Pipeline

Summary

- Immutep reported the June quarter with \$17.4M in cash and cash equivalents. At the current burn rate of \$3-4M per quarter, we estimate that Immutep has sufficient cash runway into 2H19 and through several data (catalysts) points.
- We expect to see multiple data updates in 2H18/2019 from the ongoing studies with Immutep's lead LAG-3 asset, IMP321 (eftilagimod alpha or "efti"):
 - **Breast Cancer (AIPAC):** the P2b (N=226) registration study evaluating IMP321 + chemotherapy demonstrated 87% disease control rate in the first 15 patients. The randomized portion of the trial is now underway with enrollment expected to complete YE18. Data is expected in 1H19.
 - **Melanoma (TACTI-mel):** the ongoing P1 study (N=24) combining efti with Keytruda has already demonstrated positive data (see details below), with more data expected 2H18.
 - **NSCLC, head and neck, ovarian (TACTI-002):** the P2 collaboration (N=120) with Merck is expected to initiate 2H18.
- **Conclusion:** Immutep's internal LAG-3 clinical programs continue to advance and data updates are expected over the next several quarters which if positive should continue to drive a higher valuation. We are also watching Immutep's partner's Novartis (NVS - NR) in oncology and GlaxoSmithKline (GSK - NR) in autoimmune disease (see note from 7/27) for updates, which also represent catalysts for the IMMP shares.

Details

AIPAC (Active Immunotherapy PAClitaxel): This is a randomized, double-blind, placebo-controlled Phase 2b registration study (N=226) of IMP321 (eftilagimod alpha or "efti") as an adjuvant therapy in combination with frontline paclitaxel therapy in metastatic breast cancer. Progression-free survival (PFS) is the primary endpoint. In the first phase, 15 patients (n=6 at 6-mg; n=9 at 30 mg) were evaluated primarily for safety. IMP321 was safe and well-tolerated at both dosage levels, where 47% overall response rate (ORR) and 87% disease control rate (DCR) seen with the combination in the run-in phase of the study. ORR is consistent with historical data for Avastin with paclitaxel (48.9%) in metastatic breast cancer. Interestingly, 2 of the responses observed occurred relatively late into the treatment (~6 months), which is unsurprising since delayed responses have been observed with other immunotherapies. The second phase of the trial entails randomization of 226 patients. Data is expected 1H19. Positive data may support registration of efti in metastatic breast cancer.

TACTI-mel (Two ACTive Immunotherapies in melanoma): This is a multi-center, open-label dose-escalation Phase 1 study in patients with unresectable or metastatic melanoma that have had poor responses or disease progression on Keytruda monotherapy. In the study so far, the overall response rate was 61% (11/18), including two complete responses. The data are suggestive that efti, as an immune activator, is enhancing the immune response to otherwise "cold tumors". More data is expected 2H18.

TACTI-002 (Two ACTive Immunotherapies): The Phase 2 collaboration with Merck will enroll up to N=120 in 15 centers across the US, EU. Patients with NSCLC, head and neck cancer or ovarian cancer will receive the combination therapy of efti at the 30mg dose + Keytruda. The study is expected to initiate 2H18; initial data readout 2019.

Jason McCarthy, Ph.D.
(212) 895-3556
jmccarthy@maximgrp.com

Caroline Palomeque
(212) 895-3726
cpalomeque@maximgrp.com

Income Statement (\$'000, USD)	July-Dec			Jan-Jun			July-Dec			Jan-Jun					
Immutep I: YE June 30	1H-2017A	2H-2017A	2017A	1H-2018A	2H-2018E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E		
Revenue (000's)															
Total Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-		
License revenue				2,013	2,000	4,013									
Miscellaneous income	173	443	616	259	250	509									
Grant Income	1,051	1,503	2,553	1,034	1,000	2,034									
Milestones and Royalties:															
IMP321 (Breast cancer)									5,659	14,575	44,426	57,141	65,615		
IMP321 (Melanoma)								-	-	-	10,580	20,652	30,732		
IMP731 (Psoriasis)								893	2,761	4,741	22,518	35,902	47,798		
IMP701 (Solid tumors)								1,541	4,669	8,016	18,996	24,462	30,241		
CVac															
Total Revenues	1,224	1,945	3,169	3,305	3,250	6,555	-	2,434	13,089	27,332	96,520	138,156	174,385		
Expenses															
Cost Of Goods Sold															
COGS % Sales															
Research & Development	2,086	3,499	5,585	3,625	3,698	7,323	7,689	8,073	8,477	8,901	9,346	9,813	10,304		
R&D % Rev's															
General & Administrative Expense	1,630	1,717	3,347	3,117	3,179	6,296	6,611	6,941	7,288	7,653	8,035	8,437	8,859		
SG&A %															
Depreciation and amortization		1,702	1,702	698		698									
Total expenses	3,716	6,917	10,633	7,440	6,877	14,317	14,300	15,015	15,765	16,554	17,381	18,251	19,163		
Oper. Inc. (Loss)	(2,492)	(4,972)	(7,464)	(4,134)	(3,627)	(7,761)	(14,300)	(12,581)	(2,677)	10,778	79,139	119,906	155,222		
Other income and expenses															
Interest income	49	31	80	29		29									
Loss on foreign exchange	(156)	490	333	29		29									
Finance cost															
Changes in fair value of comparability milestone															
Net Change in fair value of financial liability	(288)	(291)	(579)	337		337									
Loss on disposal of assets															
Exchange differences on the translation of foreign operations															
Total other income	(395)	521	(165)	396	-	396	-	-	-	-	-	-	-		
Pre-tax income	(2,887)	(4,451)	(7,629)	(3,739)	(3,627)	(7,366)	(14,300)	(12,581)	(2,677)	10,778	79,139	119,906	155,222		
Pretax Margin															
Taxes (or benefits)	425	313	738	0		0				539	7,914	17,986	27,940		
Tax Rate										5%	10%	15%	18%		
Exchange differences on the transactions of foreign operations		209	209	395		395									
GAAP Net Income (loss)	(2,462)	(4,347)	(7,101)	(3,344)	(3,627)	(6,970)	(14,300)	(12,581)	(2,677)	10,239	71,225	101,920	127,282		
Non GAAP Net Income (loss)	(2,462)	(4,347)	(7,101)	(3,344)	(3,627)	(7,365)	(14,300)	(12,581)	(2,677)	10,239	71,225	101,920	127,282		
GAAP -EPS	(0.12)	(0.18)	(0.32)	(0.14)	(0.13)	(0.28)	(0.53)	(0.44)	(0.09)	0.33	2.32	3.32	4.13		
Wgt'd Avg Shrs (Bas) - '000s	20,637	23,585	22,111	23,608	26,894	25,251	26,934	28,738	30,548	30,609	30,670	30,731	30,793		
Wgt'd Avg Shrs (Dil) - '000s	20,637	23,585	22,111	23,608	26,894	25,251	26,934	28,738	30,548	30,609	30,670	30,731	30,793		

Source: Company reports and Maxim

DISCLOSURES

Immutep Limited Rating History as of 07/27/2018

powered by: BlueMatrix



Maxim Group LLC Ratings Distribution		As of: 07/29/18	
		% of Coverage Universe with Rating	% of Rating for which Firm Provided Banking Services in the Last 12 months
Buy	Fundamental metrics and/or identifiable catalysts exist such that we expect the stock to outperform its relevant index over the next 12 months.	82%	34%
Hold	Fundamental metrics are currently at, or approaching, industry averages. Therefore, we expect this stock to neither outperform nor underperform its relevant index over the next 12 months.	16%	17%
Sell	Fundamental metrics and/or identifiable catalysts exist such that we expect the stock to underperform its relevant index over the next 12 months.	2%	33%

*See valuation section for company specific relevant indices

I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Caroline Palomeque, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm's total revenues, a portion of which is generated by investment banking activities.

Maxim Group makes a market in Immutep Limited

Maxim Group managed/co-managed/acted as placement agent for an offering of the securities for Immutep Limited in the past 12 months.

Maxim Group received compensation for investment banking services from Immutep Limited in the past 12 months.

Maxim Group expects to receive or intends to seek compensation for investment banking services from Immutep Limited in the next 3 months.

IMMP: For Immutep, we use the BTK (Biotechnology Index) as the relevant index.

Valuation Methods

IMMP: Our therapeutic model assumes a royalty structure for each LAG-3 product, initially with IMP701 and IMP731 in 2020 and followed by IMP321 in 2023 (breast cancer). Our models assume risk adjustments for each product based on the stage(s) of development. Our therapeutic models assume a risk adjustment. We then apply a 30% discount to our free-cash-flow, discounted EPS, and sum-of-the-parts models, which are equally weighted to derive a price target.

Price Target and Investment Risks

IMMP: Aside from general market and other economic risks, risks particular to our price target and rating for Immutep include: (1) Development—To date, LAG-3 checkpoint modulators have not been approved; (2) Regulatory—The company's ongoing and future studies may not be sufficient to gain approval; (3) Commercial—The company lacks commercial infrastructure to support a launch if approved; (4) Financial—The company is not yet profitable and may need to raise additional capital to fund operations; (5) Collaborative—The company has ongoing collaborations with large pharmaceutical companies who could back out of the partnerships, setting back development on product lines and increasing costs; (6) High volatility of the company's stock price.

RISK RATINGS

Risk ratings take into account both fundamental criteria and price volatility.

Speculative – Fundamental Criteria: This is a risk rating assigned to early-stage companies with minimal to no revenues, lack of earnings, balance sheet concerns, and/or a short operating history. Accordingly, fundamental risk is expected to be significantly above the industry. **Price Volatility:** Because of the inherent fundamental criteria of the companies falling within this risk category, the price volatility is expected to be significant with the possibility that the investment could eventually be worthless. Speculative stocks may not be suitable for a significant class of individual investors.

High – Fundamental Criteria: This is a risk rating assigned to companies having below-average revenue and earnings visibility, negative cash flow, and low market cap or public float. Accordingly, fundamental risk is expected to be above the industry. **Price Volatility:** The price volatility of companies falling within this category is expected to be above the industry. High-risk stocks may not be suitable for a significant class of individual investors.

Medium – Fundamental Criteria: This is a risk rating assigned to companies that may have average revenue and earnings visibility, positive cash flow, and is fairly liquid. Accordingly, both price volatility and fundamental risk are expected to approximate the industry average.

Low – Fundamental Criteria: This is a risk rating assigned to companies that may have above-average revenue and earnings visibility, positive cash flow, and is fairly liquid. Accordingly, both price volatility and fundamental risk are expected to be below the industry.

DISCLAIMERS

Some companies that Maxim Group LLC follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Maxim Group LLC research reports may not be suitable for some investors. Investors must make their own determination as to the appropriateness of an investment in any securities referred to herein, based on their specific investment objectives, financial status and risk tolerance.

This communication is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned herein. This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of Maxim Group, LLC ("Maxim").

Information and opinions presented in this report have been obtained or derived from sources believed by Maxim to be reliable, but Maxim makes no representation as to their accuracy or completeness. The aforementioned sentence does not apply to the disclosures required by FINRA Rule 2241. Maxim accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Maxim. This report is not to be relied upon in substitution for the exercise of independent judgment. Maxim may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and Maxim is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by Maxim and are subject to change without notice. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. The value of securities is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Securities recommended, offered or sold by Maxim: (1) are not insured by the Federal Deposit Insurance Company; (2) are not deposits or other obligations of any insured depository institution; and (3) are subject to investment risks, including the possible loss of principal invested. Indeed, in the case of some investments, the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support these losses.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST



Corporate Headquarters

The Chrysler Building
405 Lexington Ave., 2nd FL
New York, NY 10174
Tel: 212-895-3500

Capital Markets/Syndicate: 212-895-3695

Corporate Finance: 212-895-3811

Corporate Services: 212-895-3631

Equity/Options Trading: 212-895-3790

Equity Research: 212-895-3736

Fixed Income Trading: 212-895-3875

Global Equity Trading: 212-895-3623

Institutional Sales: 212-895-3873

Institutional Sales Trading: 212-895-3873

Port./Transition Trading: 212-895-3567

Prime Brokerage: 212-895-3723

Wealth Management: 212-895-3624

Woodbury, Long Island

20 Crossways Park Drive North
Suite 304
Woodbury, NY 11797
Tel: 516-393-8300

Red Bank, New Jersey

246 Maple Avenue
Red Bank, NJ 07701
Tel: 732-784-1900

West Palm Beach, Florida

105 South Narcissus Avenue
Suite 222
West Palm Beach, FL 33401
Tel: 561-508-4433

San Rafael, California

4040 Civic Center Drive
Suite 200
San Rafael, CA 94903
Tel: 212-895-3670